1. 2021
  2. A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors

    Janssen, J., Donner, N., Li, Z., Wormhoudt, T. A. M., Wagner, K., Guikema, J. E. J., van der Schoot, C. E., Kater, A. P., Feizi, T., Bende, R. J. & van Noesel, C. J. M., 2021, (E-pub ahead of print) In: HemaSphere. e550.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction

    Rolvink, J., Gerards, A-L. E., Kater, A. P., Swart, E. L. & Becker, M. L., 2021, (E-pub ahead of print) In: Journal of oncology pharmacy practice.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. 2020
  5. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

    Haselager, M. V., Kielbassa, K., ter Burg, J., Bax, D. J. C., Fernandes, S. M., Borst, J., Tam, C., Forconi, F., Chiodin, G., Brown, J. R., Dubois, J., Kater, A. P. & Eldering, E., 17 Dec 2020, In: Blood. 136, 25, p. 2918-2926 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  6. Overcoming the hurdles of autologous t‐cell‐based therapies in b‐cell non‐hodgkin lymphoma

    van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H. & Kater, A. P., 1 Dec 2020, In: Cancers. 12, 12, p. 1-31 31 p., 3837.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

    Kater, A. P., Wu, J. Q., Kipps, T., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Dubois, J., Eldering, E., Mellink, C., van der Kevie-Kersemaekers, A-M., Kim, S. Y., Chyla, B., Punnoose, E., & 8 othersBolen, C. R., Assaf, Z. J., Jiang, Y., Wang, J., Lefebure, M., Boyer, M., Humphrey, K. & Seymour, J. F., 1 Dec 2020, In: Journal of clinical oncology. 38, 34, p. 4042-4054 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Protocol description of the HOVON 141/VISION trial: A prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

    Levin, M-D., Kater, A., Mattsson, M., Kersting, S., Ranti, J., Thi Tuyet Tran, H., Nasserinejad, K. & Niemann, C. U., 15 Oct 2020, In: BMJ open. 10, 10, 039168.

    Research output: Contribution to journalArticleAcademicpeer-review

  9. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?

    Haselager, M. V., Kater, A. P. & Eldering, E., 8 Oct 2020, In: Frontiers in oncology. 10, 592205.

    Research output: Contribution to journalReview articleAcademicpeer-review

  10. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

    Scarfò, L., Chatzikonstantinou, T., Rigolin, G. M., Quaresmini, G., Motta, M., Vitale, C., Garcia-Marco, J. A., Hernández-Rivas, J. Á., Mirás, F., Baile, M. N., Marquet, J., Niemann, C. U., Reda, G., Munir, T., Gimeno, E., Marchetti, M., Quaglia, F. M., Varettoni, M., Delgado, J., Iyengar, S., & 62 othersJanssens, A., Marasca, R., Ferrari, A., Cuéllar-García, C., Itchaki, G., Špaček, M., de Paoli, L., Laurenti, L., Levin, M-D., Lista, E., Mauro, F. R., Šimkovič, M., van der Spek, E., Vandenberghe, E., Trentin, L., Wasik-Szczepanek, E., Ruchlemer, R., Bron, D., de Paolis, M. R., del Poeta, G., Farina, L., Foglietta, M., Gentile, M., Herishanu, Y., Herold, T., Jaksic, O., Kater, A. P., Kersting, S., Malerba, L., Orsucci, L., Popov, V. M., Sportoletti, P., Yassin, M., Pocali, B., Barna, G., Chiarenza, A., dos Santos, G., Nikitin, E., Andres, M., Dimou, M., Doubek, M., Enrico, A., Hakobyan, Y., Kalashnikova, O., Ortiz Pareja, M., Papaioannou, M., Rossi, D., Shah, N., Shrestha, A., Stanca, O., Stavroyianni, N., Strugov, V., Tam, C., Zdrenghea, M., Coscia, M., Stamatopoulos, K., Rossi, G., Rambaldi, A., Montserrat, E., Foà, R., Cuneo, A. & Ghia, P., 1 Sep 2020, In: Leukemia. 34, 9, p. 2354-2363 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  11. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

    Saberi Hosnijeh, F., van der Straten, L., Kater, A. P., van Oers, M. H. J., Posthuma, W. F. M., Chamuleau, M. E. D., Bellido, M., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., de Boer, F., te Raa, G. D., Kerst, J. M., Marijt, E. W. A., Raymakers, R. A. P., Koene, H. R., Schaafsma, M. R., Dobber, J. A., Tonino, S. H., Kersting, S. S., & 2 othersLangerak, A. W. & Levin, M-D., Sep 2020, In: Experimental hematology. 89, p. 55-60.e6

    Research output: Contribution to journalArticleAcademicpeer-review

  12. COVID-19 among fit patients with CLL treated with venetoclax-based combinations

    Fürstenau, M., Langerbeins, P., de Silva, N., Fink, A. M., Robrecht, S., von Tresckow, J., Simon, F., Hohloch, K., Droogendijk, J., van der Klift, M., van der Spek, E., Illmer, T., Schöttker, B., Fischer, K., Wendtner, C. M., Tausch, E., Stilgenbauer, S., Niemann, C. U., Gregor, M., Kater, A. P., & 2 othersHallek, M. & Eichhorst, B., 1 Aug 2020, In: Leukemia. 34, 8, p. 2225-2229 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

Previous 1 2 3 4 5 6 7 8 ...20 Next

ID: 64520